|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2003-11-4
|
|
pubmed:abstractText |
Trimetazidine (TMZ) has been shown to partially inhibit free fatty acid oxidation by shifting substrate utilization from fatty acid to glucose. The aim of this study was to assess the effects of TMZ in patients with diabetes and ischemic cardiomyopathy.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1097-6744
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
146
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
E18
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14597947-Aged,
pubmed-meshheading:14597947-Diabetes Mellitus, Type 2,
pubmed-meshheading:14597947-Double-Blind Method,
pubmed-meshheading:14597947-Echocardiography,
pubmed-meshheading:14597947-Energy Metabolism,
pubmed-meshheading:14597947-Glucose,
pubmed-meshheading:14597947-Humans,
pubmed-meshheading:14597947-Male,
pubmed-meshheading:14597947-Middle Aged,
pubmed-meshheading:14597947-Myocardial Ischemia,
pubmed-meshheading:14597947-Myocardium,
pubmed-meshheading:14597947-Trimetazidine
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.
|
|
pubmed:affiliation |
Clinical Cardiology-Heart Failure Unit, Universitá degli Studi di Milano, Istituto Scientifico/Universitá San Raffaele, Milano, Italy. gabriele.fragasso@hsr.it
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
